Flerie Invest AB is pursuing a public mandatory offer for Lipum AB, subject to regulatory approvals, positioning itself for enhanced growth in the biotechnology sector.

Information on the Target

Flerie Invest AB ("Flerie") has announced a public mandatory offer for the shareholders and convertible bondholders of Lipum AB (publ) ("the Offer"). This strategic move aims to consolidate Flerie's holdings in Lipum, a biotechnology company focused on developing innovative therapeutic solutions. The Offer is subject to obtaining all necessary approvals and permits from relevant authorities, including the Swedish Inspectorate for Strategic Products (ISP), under the Foreign Direct Investment Act.

As of March 28, 2024, Flerie received notice from the ISP indicating that the notification regarding the mandatory offer is deemed without action, thereby fulfilling one of the conditions of the Offer. The acceptance period for the Offer concludes on April 4, 2024, with expected settlement of compensation around April 11, 2024.

Industry Overview in Sweden

Sweden boasts a robust biotechnology and pharmaceutical industry, characterized by a strong commitment to innovation and research. The country is home to numerous biotech firms, many of which are dedicated to drug de